CDK1-IN-2

CAS No. 220749-41-7

CDK1-IN-2( —— )

Catalog No. M35812 CAS No. 220749-41-7

CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM. A broad-spectrum kinase profiling of CDK1-IN-2 revealed nonselective inhibition of several kinases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 100 In Stock
5MG 104 In Stock
10MG 169 In Stock
25MG 353 In Stock
50MG 555 In Stock
100MG 792 In Stock
200MG Get Quote In Stock
500MG 1609 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CDK1-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM. A broad-spectrum kinase profiling of CDK1-IN-2 revealed nonselective inhibition of several kinases.
  • Description
    CDK1-IN-2 is a CDK1 inhibitor (IC50: 5.8 μM).
  • In Vitro
    CDK1-IN-2 (“CDK1 inhibitor 1”, 0-19.8 μM, 24 h) arrests HCT-116 cells in G2/M phase.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    220749-41-7
  • Formula Weight
    294.73
  • Molecular Formula
    C17H11ClN2O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 250 mg/mL (848.21 mM )
  • SMILES
    Clc1[nH]c2ccccc2c1\C=C1\C(=O)Nc2ccccc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Jorda R, et al. How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? J Med Chem. 2018 Oct 25;61(20):9105-9120. ?
molnova catalog
related products
  • CYC065

    CYC065 is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9.

  • Roscovitine

    A potent and selective CDK inhibitor with IC50 of 0.2 uM, 0.65 uM, and 0.7 uM for CDK5, Cdc2, and CDK2, respectively.

  • Atuveciclib

    Atuveciclib (BAY-1143572) is a potent, highly selective, orally bioavailable CDK9/P-TEFb inhibitor with IC50 of 6 nM for CDK9/CyclinT1.